Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 56)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Nitric Oxide |
Approved |
Phase 4 |
|
10102-43-9 |
145068
|
Synonyms:
(.)NO
(no)(.)
(NO)(.)
[no]
[NO]
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous nitrate vasodilator
Endogenous Nitrate Vasodilator
Endothelium-derived nitric oxide
Endothelium-Derived Nitric Oxide
endothelium-derived relaxing factor
Endothelium-derived relaxing factor
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, Mononitrogen
Monoxide, nitrogen
Monoxide, Nitrogen
monoxido de nitrogeno
monoxido De nitrogeno
Monoxido de nitrogeno
monoxyde d'azote
Monoxyde d'azote
Nitrate vasodilator, endogenous
Nitrate Vasodilator, Endogenous
nitric oxide
|
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, endothelium derived
Nitric Oxide, Endothelium Derived
Nitric oxide, endothelium-derived
Nitric Oxide, Endothelium-Derived
NITRIC-OXIDE
nitrogen monooxide
Nitrogen monooxide
nitrogen monoxide
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
nitrosyl
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
no(.)
NO(.)
OHM 11771
Oxide, nitric
Oxide, Nitric
óxido de nitrógeno(2)
oxido de nitrogeno(II)
oxido De nitrogeno(II)
Oxido de nitrogeno(ii)
oxido nitrico
oxido Nitrico
Oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(ii)-oxid
Stickstoff(II)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, endogenous nitrate
Vasodilator, Endogenous Nitrate
|
|
2 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 4,Phase 3 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
3 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4,Phase 3 |
|
83-43-2 |
6741
|
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-dehydro-6alpha-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6a-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6-Methylprednisolone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
Medrate
Medric acid
|
Medrol
Medrol (TN)
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
δ(1)-6a-methylhydrocortisone
δ(1)-6α-methylhydrocortisone
|
|
4 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4,Phase 3 |
|
50-24-8 |
5755
|
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-pregnadiene-3,20-dione-11β,17α,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11b,17a,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Bio-0666
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
Codelcortone
Co-Hydeltra
CO-Hydeltra
component of Ataraxoid
component of K-Predne-Dome
Cordrol
Cortalone
Cotogesic
Cotolone
CPD000718761
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
delta(1)-Cortisol
delta(1)-Dehydrocortisol
Delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
Delta(1)-dehydrohydrocortisone
Delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Deltacortenol
Deltacortril
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
Delta-Ef-Cortelan
delta-hydrocortisone
Deltahydrocortisone
Deltasolone
Delta-stab
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
Derpo PD
Dexa-Cortidelt hostacortin H
Dexa-Cortidelt Hostacortin H
Di adreson F
Di Adreson F
Di-adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Di-Adreson-F
Dicortol
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
EINECS 200-021-7
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
Hostacortin H
HSDB 3385
Hydeltra
Hydeltrasol
Hydeltra-Tba
|
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
Inflamase Forte
Inflamase Mild
I-Pred
K 1557
Key-Pred
Klismacort
Lentosone
Lite Pred
LMST02030179
LS-7669
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
Methylprednisolone Acetate
Meticortelone
Meti-Derm
Metreton
MLS001304083
MLS002154250
MLS002207037
MolPort-002-507-147
M-Predrol
NCGC00179649-01
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
NSC 9120
NSC9120
NSC9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
PRDL
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
prednisolone
Prednisolone (anhydrous)
Prednisolone (JP15/USP/INN)
Prednisolone [INN:BAN:JAN]
Prednisolone acetate
Prednisolone Acetate
Prednisolone sodium phosphate
Prednisolone Sodium Phosphate
Prednisolone tebutate
Prednisolone Tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick_404
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Rolisone
S1737_Selleck
SAM002264639
Scherisolon
SMR000718761
Solone
SPBio_002367
Steran
Sterane
Sterolone
Supercortisol
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-hydrogen
Ultracortene-Hydrogen
UNII-9PHQ9Y1OLM
ZINC03833821
δ(1)-dehydrocortisol
δ(1)-dehydrohydrocortisone
δ(1)-hydrocortisone
|
|
5 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 4,Phase 3 |
|
2921-57-5 |
|
Synonyms:
Methylprednisolone hydrogen succinate
|
Methylprednisolone succinate
|
|
6 |
|
Omalizumab |
Approved, Investigational |
Phase 4,Phase 2 |
|
242138-07-4 |
|
Synonyms:
242138-07-4
D05251
Omalizumab
Omalizumab (genetical recombination)
|
Omalizumab (genetical recombination) (JAN)
Omalizumab (USAN/INN)
Xolair
Xolair (TN)
|
|
7 |
|
Ciclesonide |
Approved, Investigational |
Phase 4 |
|
141845-82-1, 126544-47-6 |
444033
|
Synonyms:
(R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
126544-47-6
141845-82-1
AC-1330
Alvesco
Alvesco (TN)
Alvesco HFA
B-9207-015
BTR-15
BTR-15K
BY-9010
BYK-20426
Ciclesonide
Ciclesonide (JAN/USAN/INN)
Ciclesonide [INN]
|
CID6918155
D01703
KS-1165
LS-186047
MolPort-005-940-705
NCGC00167972-01
Omnair
Omnaris
Omnaris HFA
Osonase
Osonide
RPR 251526
TBN-15
UNII-S59502J185
|
|
8 |
|
Prednisone |
Approved, Vet_approved |
Phase 4,Phase 2,Phase 3 |
|
53-03-2 |
5865
|
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
Acis brand OF prednisone
ACon0_000082
ACon1_000297
Adasone
AI3-52939
Ancortone
apo-Prednisone
Apo-prednisone
Apo-Prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Bio-0649
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
C07370
C21H26O5
Cartancyl
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
CPD001227202
Cutason
Dacorten
Dacortin
DB00635
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
delta cortelan
Delta Cortelan
Delta E
Delta E.
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
Delta-cortelan
Delta-Cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Delta-cortisone
delta-Cortone
Deltacortone
Delta-cortone
Delta-dome
Delta-Dome
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
EINECS 200-160-3
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
Fernisone
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
HMS1568O15
HMS2090J13
|
Hoechst brand OF prednisone
Hostacortin
HSDB 3168
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
Liquid pred
Liquid Pred
Lisacort
LMST02030180
Lodotra
LS-1325
MEGxm0_000443
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
Mibe brand OF prednisone
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI60_000008
NCI-C04897
Nisona
Nizon
Novoprednisone
NSC 10023
NSC10023
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
Predni tablinen
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone [INN:BAN]
Prednisone Intensol
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick_405
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
Servisone
SK-Prednisone
SMR000718760
SMR001227202
Solvay brand OF prednisone
Sone
SPBio_002214
Sterapred
Supercortil
Trommsdorff brand OF prednisone
U 6020
Ultracorten
Ultracortene
UNII-VB0R961HZT
Winpred
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Wojtab
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
ZINC03875357
|
|
9 |
|
Reslizumab |
Approved, Investigational |
Phase 4,Phase 3,Phase 2 |
|
|
|
10 |
|
Budesonide |
Approved |
Phase 4 |
|
51333-22-3 |
63006
5281004
|
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
AC-4697
B 7777
B7777_SIGMA
Bidien
Bio-0010
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Budecort Inhaler
Budenofalk
Budeson
budesonide
Budesonide (JAN/USAN/INN)
Budesonide [USAN:INN:BAN:JAN]
Budesonide Easyhaler
Budesonide MMX
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
Cortivent
CPD000058337
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
Entocort
Entocort EC
Entocort EC (TN)
EU-0100174
Giona Easyhaler
HMS1569H17
HMS1921I22
HMS2094I13
|
HMS501H17
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
Lopac0_000174
LS-187734
LS-7235
MAP-0010
Micronyl
Miflonide
MLS000028507
MLS001077323
MLS002207112
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick_840
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort turbuhaler
Pulmicort Turbuhaler
Respules
Rhinocort
Rhinocort alpha
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S1286_Selleck
S-1320
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
ST51039033
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
|
|
11 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 4,Phase 3 |
|
2920-86-7 |
|
Synonyms:
(+)-prednisolone hemisuccinate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
Prednisolone hydrogen succinate
Prednisolone succinate
|
|
12 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
13 |
|
Anti-Inflammatory Agents |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
14 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
15 |
|
Hormone Antagonists |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
16 |
|
Peripheral Nervous System Agents |
|
Phase 4,Phase 2 |
|
|
|
17 |
|
Hormones |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
18 |
|
Methylprednisolone acetate |
|
Phase 4,Phase 3 |
|
|
|
19 |
|
Prednisolone acetate |
|
Phase 4,Phase 3 |
|
|
|
20 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
21 |
|
Antiemetics |
|
Phase 4 |
|
|
|
22 |
|
Autonomic Agents |
|
Phase 4,Phase 2 |
|
|
|
23 |
|
glucocorticoids |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
24 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
25 |
|
Protective Agents |
|
Phase 4 |
|
|
|
26 |
|
Anti-Asthmatic Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
27 |
|
Neurotransmitter Agents |
|
Phase 4,Phase 2 |
|
|
|
28 |
|
Adrenergic beta-Agonists |
|
Phase 4,Phase 2 |
|
|
|
29 |
|
Adrenergic Agonists |
|
Phase 4,Phase 2 |
|
|
|
30 |
|
Adrenergic Agents |
|
Phase 4,Phase 2 |
|
|
|
31 |
|
Antibodies, Monoclonal |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
32 |
|
Anti-Allergic Agents |
|
Phase 4,Phase 2 |
|
|
|
33 |
|
Antibodies |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
34 |
|
Respiratory System Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
35 |
|
Tocolytic Agents |
|
Phase 4,Phase 2 |
|
|
|
36 |
|
Adrenergic beta-2 Receptor Agonists |
|
Phase 4,Phase 2 |
|
|
|
37 |
|
Immunologic Factors |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
38 |
|
Bronchodilator Agents |
|
Phase 4,Phase 2 |
|
|
|
39 |
|
Immunoglobulins |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
40 |
|
Albuterol |
|
Phase 4,Phase 2 |
|
|
|
41 |
|
Fluorodeoxyglucose F18 |
|
Phase 4 |
|
|
|
42 |
|
Radiopharmaceuticals |
|
Phase 4 |
|
|
|
43 |
|
Citric Acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311
|
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
44 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
45 |
|
Pharmaceutical Solutions |
|
Phase 3,Phase 2 |
|
|
|
46 |
|
Citrate |
|
Phase 3 |
|
|
|
47 |
|
Fluticasone |
Approved, Experimental |
Phase 2 |
|
90566-53-3 |
62924
|
Synonyms:
90566-53-3
AC1NSJZT
AC-456
BIDD:GT0819
C07815
CHEMBL1201396
CID5311101
D07981
Fluticaps
|
Fluticaps (TN)
Fluticason
Fluticasona
fluticasone
Fluticasone
Fluticasone (INN)
Fluticasonum
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
|
|
48 |
|
Sympathomimetics |
|
Phase 2 |
|
|
|
49 |
|
Salmeterol xinafoate |
|
Phase 2 |
|
94749-08-3 |
56801
|
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
GR-33343 G
|
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
salmeterol xinafoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent diskus
Serevent Inhaler and Disks
SMR000875207
Ultrabeta
UNII-6EW8Q962A5
|
|
50 |
|
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 43)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia |
Completed |
NCT00632554
|
Phase 4 |
prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months |
2 |
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients |
Completed |
NCT02654145
|
Phase 4 |
Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab |
3 |
Small Particle Steroids in Refractory Asthma |
Completed |
NCT01171365
|
Phase 4 |
Ciclesonide;Placebo |
4 |
Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma |
Recruiting |
NCT03610685
|
Phase 4 |
Prednisolone;Placebo oral capsule |
5 |
The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma |
Recruiting |
NCT03034005
|
Phase 4 |
Budesonide |
6 |
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma |
Not yet recruiting |
NCT03652376
|
Phase 4 |
Benralizumab |
7 |
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation |
Terminated |
NCT02937168
|
Phase 4 |
Reslizumab;Fludeoxyglucose F 18 (FDG);Placebo |
8 |
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma |
Completed |
NCT01285323
|
Phase 3 |
Reslizumab;Placebo |
9 |
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma |
Completed |
NCT01287039
|
Phase 3 |
Reslizumab;Placebo |
10 |
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma |
Completed |
NCT01270464
|
Phase 3 |
Reslizumab;Placebo |
11 |
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control |
Completed |
NCT02281318
|
Phase 3 |
Placebo;SOC |
12 |
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma |
Completed |
NCT03052725
|
Phase 3 |
reslizumab |
13 |
Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma |
Completed |
NCT02559791
|
Phase 2, Phase 3 |
Placebo |
14 |
Study of Mepolizumab Autoinjector in Asthmatics |
Completed |
NCT03099096
|
Phase 3 |
Mepolizumab |
15 |
Study of Mepolizumab Safety Syringe in Asthmatics |
Completed |
NCT03021304
|
Phase 3 |
Mepolizumab |
16 |
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma |
Completed |
NCT01508936
|
Phase 3 |
Reslizumab;Placebo |
17 |
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects |
Completed |
NCT02135692
|
Phase 3 |
SOC |
18 |
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients |
Recruiting |
NCT02555371
|
Phase 3 |
Placebo |
19 |
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies |
Recruiting |
NCT03470311
|
Phase 3 |
|
20 |
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma |
Recruiting |
NCT03557307
|
Phase 3 |
|
21 |
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) |
Recruiting |
NCT02836496
|
Phase 3 |
Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules |
22 |
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma |
Terminated |
NCT01290887
|
Phase 3 |
Reslizumab |
23 |
Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study |
Terminated |
NCT02594332
|
Phase 3 |
Mepolizumab;Placebo |
24 |
A Phase IIa Study of KHK4563 |
Completed |
NCT01412736
|
Phase 2 |
KHK4563;KHK4563;KHK4563;Placebo |
25 |
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma |
Completed |
NCT01312961
|
Phase 2 |
Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol |
26 |
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma |
Completed |
NCT02560610
|
Phase 2 |
OC000459;Placebo |
27 |
Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children |
Completed |
NCT02377427
|
Phase 2 |
Mepolizumab |
28 |
Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma |
Recruiting |
NCT03469934
|
Phase 2 |
ANB020;Placebo |
29 |
Pregnancy Rate, Asthma, Infertility, Omalizumab |
Recruiting |
NCT03727971
|
Phase 2 |
Omalizumab Injection;NaCl |
30 |
GB001 in Adult Subjects With Moderate to Severe Asthma |
Recruiting |
NCT03683576
|
Phase 2 |
GB001;Placebo Oral Tablet |
31 |
Effect of Benralizumab in Atopic Dermatitis |
Not yet recruiting |
NCT03563066
|
Phase 2 |
Benralizumab;Placebo Control |
32 |
Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia |
Unknown status |
NCT01152424
|
|
|
33 |
Intense Airway Eosinophilia in Asthma |
Completed |
NCT03696914
|
|
|
34 |
Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma |
Completed |
NCT03453021
|
|
Mepolizumab |
35 |
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center |
Completed |
NCT03209934
|
|
|
36 |
A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma |
Recruiting |
NCT03739320
|
|
Mepolizumab 100 MG Injection [Nucala] |
37 |
Exploring Asthma Exacerbations in Mepolizumab Treated Patients |
Recruiting |
NCT03324230
|
|
|
38 |
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma |
Recruiting |
NCT03563521
|
|
|
39 |
Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab |
Recruiting |
NCT03369574
|
|
Reslizumab |
40 |
European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank |
Recruiting |
NCT02852928
|
|
|
41 |
Real-world Daptomycin Use in Chinese ICUs |
Recruiting |
NCT03588637
|
|
|
42 |
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) |
Recruiting |
NCT03373045
|
|
|
43 |
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI |
Not yet recruiting |
NCT03733535
|
Not Applicable |
Benralizumab;129 Xenon |
|